Skip to content
Calculator
Evidence: LowPeptideResearch ChemicalEndogenous β-defensinPsoriasis markerNot a medicine

hBD-2

The skin's inducible antibiotic, first found in psoriasis scales and now studied as a disease marker

Human beta-defensin 2 is made by skin and other epithelia when they meet microbes or inflammation. It was first isolated from psoriasis scales, and its levels track psoriasis in many studies; in one analysis, baseline blood levels predicted response to an approved psoriasis antibody. It is not an approved drug.

At a Glance Read Research →
Overview

What is it?

hBD-2 was the first inducible human defensin to be described, cloned in 1997 from the scales of psoriasis lesions. Where hBD-1 is always present, hBD-2 is switched on when skin or mucosa meets bacteria, fungi or inflammatory signals, and it acts as both an antibiotic and a signal to the immune system.

That signalling role was shown in 1999, when beta-defensins were found to attract immature dendritic cells and memory T cells through the chemokine receptor CCR6, linking the first-line innate defence to the adaptive immune system. A 2024 review describes hBD-2 as a bridge between infection and allergic skin disease, including its effects on mast cells.

Most human research measures it. In blood it separated infection from non-infectious inflammation better than procalcitonin or CRP in one study of 114 people, and low sputum levels marked COPD patients who went on to exacerbate. In psoriasis, hBD-2 is highly expressed in lesions and tracked severity in a 2024 study; serum levels were raised in psoriasis and psoriatic arthritis in a 2026 case-control study but did not correlate with disease activity there. In a proteomics analysis of psoriatic arthritis trials, baseline serum BD-2 predicted response to secukinumab, an approved IL-17A antibody, but not to placebo, a finding validated in two further studies.

hBD-2 is not an approved treatment and has no established human dose. Its value so far is as a biological signal and a research tool; anything sold online under its name is a research chemical.

Structured data

At a Glance

Every value in this table is printed from the Grey Peptides dataset, the same record the compound explorer and comparison tool read, so the three can never disagree.

ClassA 41-amino-acid cationic antimicrobial β-defensin expressed inducibly by epithelial cells in response to bacterial products and pro-inflammatory cytokines; markedly upregulated in psoriatic skin, where it was originally isolated.
SequenceGIGDPVTCLKSGAICHPVFCPRRYKQIGTCGLPGTKCCKKP (disulfides Cys8-Cys37, Cys15-Cys30, Cys20-Cys38)
FormulaC188H305N55O50S6
Molecular weight4328.2 g/mol
Half-lifenot applicable — endogenous epithelial peptide
US statusResearch Chemical
Evidence levelLow
Last reviewed2026-10-05
Evidence

Published Research

These studies were read from their PubMed abstracts on October 5, 2026.

Human2023

Predicting response to secukinumab

In serum proteomics from psoriatic arthritis trials, baseline beta-defensin 2 was robustly associated with later clinical response to secukinumab but not to placebo, validated in two independent studies, from 4 weeks to 52 weeks, and independent of baseline psoriasis severity.

PMID: 37321668
Human2024

Lesion levels and psoriasis severity

hBD-2, with CXCL-1 and CXCL-2, was highly expressed in psoriasis vulgaris lesions and correlated positively with severity scores; together they diagnosed psoriasis and severe disease better than any one alone.

PMID: 39301953
Human2026

Serum levels in psoriasis and psoriatic arthritis

Serum hBD-2 was higher in psoriasis and psoriatic arthritis than in controls but did not differ between the two patient groups and did not correlate with PASI, CRP or ESR.

PMID: 41689371
Human2023

Telling infection from inflammation

In 423 serum samples from 114 people, hBD-2 was markedly higher in infection than in non-infectious inflammation or health and separated infection better (AUC 0.897) than procalcitonin (0.576) or CRP, including during the first 5 days in hospital.

PMID: 37296737
Human2023

COPD exacerbations

Over two years in 254 people from Guangzhou, sputum hBD-2 was lower in COPD patients who had an exacerbation than in those who had none (1,131 against 2,104 pg/mL), and a level below 1,000 pg/mL was associated with exacerbations.

PMID: 37003996
In Vitro1999

A link to adaptive immunity

Human beta-defensins were selectively chemotactic for immature dendritic cells and memory T cells through the chemokine receptor CCR6, an effect blocked by antibodies to CCR6.

PMID: 10521347
Review2024

Infection and allergic skin disease

A review of hBD-2's role between infection and allergic skin conditions, including its promotion of mast cell activation and degranulation.

PMID: 39324351
Safety

Side Effects & Contraindications

Reported Side Effects

Not applicable.

● hBD-2 is not an approved treatment; no side-effect profile exists for therapeutic use
● Any product sold as hBD-2 is untested for human use

Contraindications & Cautions

Not a medicine, so there is no label and no formal contraindication.

● No approved product exists; nothing sold as this peptide has been tested in people as a treatment
● Research-grade material has no quality control for human use
Questions

Frequently Asked Questions

?What is hBD-2?

An antimicrobial peptide that skin and mucosa make when they meet microbes or inflammation, first found in psoriasis scales.

?Is hBD-2 a psoriasis test?

Not a routine one. It tracks psoriasis in many studies and predicted response to secukinumab in one analysis, but it is a research marker.

?Can you take hBD-2?

No approved product exists and no human dose has been established.

Bibliography

References

  1. [pubmed] Cardner M, et al. "Analysis of serum proteomics data identifies a quantitative association between beta-defensin 2 at baseline and clinical response to IL-17 blockade in psoriatic arthritis." RMD Open, 2023;9(2). PMID: 37321668.
  2. [pubmed] Lin L, et al. "Correlation and Clinical Significance of HBD-2 and CXCL-1/2 Levels at Skin Lesions with Psoriasis Vulgaris Severity." Immunol Invest, 2024;53(8):1234-1249. PMID: 39301953.
  3. [pubmed] Kaya NE, et al. "Investigating the role of serum human beta defensin-2 in psoriasis and psoriatic arthritis: a case-control study on hBD-2 and CRP, ESR." Cutan Ocul Toxicol, 2026;45(3):335-341. PMID: 41689371.
  4. [pubmed] Yang D, et al. "Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6." Science, 1999;286(5439):525-8. PMID: 10521347.
  5. [pubmed] Štrajtenberger M, et al. "Human β-defensin 2: a connection between infections and allergic skin diseases." Acta Dermatovenerol Alp Pannonica Adriat, 2024;33(3):135-139. PMID: 39324351.
  6. [pubmed] Harder J, et al. "A peptide antibiotic from human skin." Nature, 1997;387(6636):861. PMID: 9202117.
  7. [pubmed] Pazgier M, et al. "Human beta-defensins." Cell Mol Life Sci, 2006;63(11):1294-313. PMID: 16710608.
  8. [pubmed] Routsias JG, et al. "Serum β-Defensin 2, A Novel Biomarker for the Diagnosis of Acute Infections." Diagnostics (Basel), 2023;13(11). PMID: 37296737.
  9. [pubmed] Feng S, et al. "Low human beta-defensin-2 levels in the sputum of COPD patients are associated with the risk of exacerbations." BMC Pulm Med, 2023;23(1):106. PMID: 37003996.

Sources & Citations

Studies from their PubMed abstracts, read October 5, 2026.

Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Consult a licensed healthcare provider before making health decisions.

Last reviewed: 2026-10-05